Context Therapeutics Inc (CNTX)

$0.94 -0.06 (-6.00%)
Market Cap 89.70M
Revenue (ttm) 0.00
Net Income (ttm) -26.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 56,300
Avg Vol 167,698
Day's Range N/A - N/A
Shares Out 89.70M
Stochastic %K 64%
Beta 2.18
Analysts Strong Sell
Price Target $5.50

Latest News on CNTX

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

Apr 9, 2025, 7:30 AM EDT - 16 days ago

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

Context Therapeutics to Participate in Upcoming Investor Conferences

Apr 1, 2025, 7:30 AM EDT - 24 days ago

Context Therapeutics to Participate in Upcoming Investor Conferences

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 26, 2025, 4:02 PM EDT - 4 weeks ago

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

Mar 20, 2025, 4:22 PM EDT - 5 weeks ago

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 24, 2025, 5:05 PM EST - 2 months ago

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Jan 14, 2025, 4:58 PM EST - 3 months ago

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Jan 13, 2025, 7:30 AM EST - 3 months ago

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Nov 6, 2024, 4:06 PM EST - 6 months ago

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Context Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 23, 2024, 7:30 AM EDT - 6 months ago

Context Therapeutics to Participate in Upcoming Investor Conferences in November

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 16, 2024, 7:30 AM EDT - 6 months ago

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

Sep 4, 2024, 7:30 AM EDT - 8 months ago

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Aug 7, 2024, 4:17 PM EDT - 9 months ago

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Aug 1, 2024, 7:30 AM EDT - 9 months ago

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline

Jul 10, 2024, 2:06 PM EDT - 10 months ago

Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

Jul 10, 2024, 7:30 AM EDT - 10 months ago

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

May 8, 2024, 4:06 PM EDT - 1 year ago

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

May 2, 2024, 7:31 AM EDT - 1 year ago

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Apr 1, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Mar 21, 2024, 7:43 AM EDT - 1 year ago

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Nov 9, 2023, 4:15 PM EST - 1 year ago

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 1 year ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 9, 2023, 4:10 PM EDT - 1 year ago

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Context Therapeutics to Participate in Two August 2023 Investor Conferences

Aug 1, 2023, 7:30 AM EDT - 1 year ago

Context Therapeutics to Participate in Two August 2023 Investor Conferences

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

May 10, 2023, 4:39 PM EDT - 2 years ago

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

Apr 18, 2023, 10:15 AM EDT - 2 years ago

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

Context Therapeutics to Participate in Two April 2023 Investor Conferences

Apr 3, 2023, 7:30 AM EDT - 2 years ago

Context Therapeutics to Participate in Two April 2023 Investor Conferences

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Mar 22, 2023, 5:08 PM EDT - 2 years ago

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 15, 2023, 7:30 AM EDT - 2 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

Feb 6, 2023, 7:30 AM EST - 2 years ago

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

Jan 31, 2023, 7:30 AM EST - 2 years ago

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

Jan 9, 2023, 7:30 AM EST - 2 years ago

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

Jan 4, 2023, 7:30 AM EST - 2 years ago

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Dec 8, 2022, 7:30 AM EST - 2 years ago

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

Nov 29, 2022, 7:30 AM EST - 2 years ago

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

Nov 21, 2022, 9:11 AM EST - 2 years ago

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Nov 9, 2022, 4:14 PM EST - 2 years ago

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Context Therapeutics to Participate in the ThinkEquity Conference

Oct 20, 2022, 7:30 AM EDT - 2 years ago

Context Therapeutics to Participate in the ThinkEquity Conference

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

Sep 27, 2022, 7:30 AM EDT - 2 years ago

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 7:30 AM EDT - 2 years ago

Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results

Aug 11, 2022, 4:01 PM EDT - 2 years ago

Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Aug 2, 2022, 9:59 AM EDT - 2 years ago

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results

May 11, 2022, 4:01 PM EDT - 3 years ago

Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results

Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Apr 11, 2022, 7:30 AM EDT - 3 years ago

Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Context Therapeutics® to Participate in Two April 2022 Investor Conferences

Apr 6, 2022, 7:30 AM EDT - 3 years ago

Context Therapeutics® to Participate in Two April 2022 Investor Conferences

Context Therapeutics® Reports Full Year 2021 Operating and Financial Results

Mar 23, 2022, 4:01 PM EDT - 3 years ago

Context Therapeutics® Reports Full Year 2021 Operating and Financial Results

Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Mar 8, 2022, 6:12 PM EST - 3 years ago

Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Context Therapeutics® to Participate in the Sachs 15th Annual European Life Sciences CEO Forum

Feb 22, 2022, 7:30 AM EST - 3 years ago

Context Therapeutics® to Participate in the Sachs 15th Annual European Life Sciences CEO Forum

Context Therapeutics® Strengthens Research & Development Team

Jan 5, 2022, 4:01 PM EST - 3 years ago

Context Therapeutics® Strengthens Research & Development Team

Context Therapeutics® to Participate in Two January 2022 Investor Conferences

Jan 4, 2022, 7:30 AM EST - 3 years ago

Context Therapeutics® to Participate in Two January 2022 Investor Conferences

Context Therapeutics Shares Surge On Encouraging Data From Onapristone In Early Breast Cancer

Dec 10, 2021, 6:45 AM EST - 3 years ago

Context Therapeutics Shares Surge On Encouraging Data From Onapristone In Early Breast Cancer